Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) ...

Welcome to Madrigal Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. (Operator Instructions) As a reminder, today's conference call is being recorded. I'd like to introduce Ms. Tina ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $405 from $400 and keeps a Buy rating on the shares ...

Rezdiffra reduced liver stiffness by 6.7 kPa at two years, with 51% of patients showing ≥25% improvement in MASH cirrhosis. Madrigal posted a Q4 loss of $2.71 per share, beating estimates ...

Madrigal's financial performance has been bolstered by Rezdiffra's success. The company's ability to generate substantial revenue from a single product in its first year post-approval is ...

The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a ...